CRISPR-Cas9 has been touted for therapeutic genome editing, but limitations include inefficient correction of disease-causing mutations and off-target mutagenesis. In the latest issue of Cell, Liao et al. (2017) show that a modified version of CRISPR-Cas9 can target and activate key therapeutic genes in vivo without altering DNA sequence identity.

中文翻译：

---

通过治疗表观基因组编辑提高热度。

CRISPR-Cas9被吹捧用于治疗性基因组编辑，但局限性包括对致病突变和脱靶诱变的低效校正。在最新一期的Cell中，Liao等人。（2017）表明，CRISPR-Cas9的改良版可以在体内靶向和激活关键治疗基因，而不会改变DNA序列同一性。